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Summary
von Willebrand’s disease (VWD) is probably the most common bleeding disorder, with some
studies indicating that up to 1% of the population may have the condition. Over recent years
interest in VWD has fallen compared to that of haemophilia, partly the result of focus on blood-
borne diseases such as HIV and hepatitis. Now the time has come to revisit VWD, and in view of
this some 60 international physicians with clinical and scientific interest in VWD met over 4 days
in 2010 in the Åland islands to discuss state-of-the-art issues in the disease. The Åland islands are
where Erik von Willebrand had first observed a bleeding disorder in a number of members of a
family from Föglö, and 2010 was also the 140th anniversary of his birth. This report summarizes
the main papers presented at the symposium; topics ranged from genetics and biochemistry
through to classification of VWD, pharmacokinetics and laboratory assays used in the diagnosis of
the disease, inhibitors, treatment guidelines in different age groups including the elderly who often
have comorbid conditions that present challenges, and prophylaxis. Other topics included
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managing surgeries in patients with VWD and the role of FVIII in VWF replacement, a
controversial subject.
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Introduction (Erik Berntorp)
In September 2010, a group of around 60 physicians from all over the world with clinical
and scientific interest in von Willebrand’s disease (VWD) met to give an update on current
research and treatment in VWD. It was also the 140th anniversary of the birth of Erik von
Willebrand (1870–1949) who in 1926 published his first article on a bleeding disorder that
he had observed in a number of members of a family from Föglö in the Åland islands (1; see
Fig. 1). His first case was a 5-year-old girl, Hjördis S., who had bleeding symptoms, as did
most of her 11 siblings [2]. During her fourth menstrual period at the age of 13, Hjö rdis
bled to death, as had four of her sisters before her from bleeding from the nose, wounds
and/or the intestinal canal (Fig. 2). von Willebrand published several articles describing the
disease [3,4], and his descriptions are still relevant today.
Progress in the understanding of VWD over the last 50 years (Ian Peake)
von Willebrand’s disease is a common inherited bleeding disorder, characterized by a
deficiency of plasma (and platelet) von Willebrand factor (VWF) and factor VIII (FVIII)
which result in mucocutaneous bleeding. Classification and diagnosis of VWD is important
to identify the prognosis and correct treatment for the individual patient. There have been
many articles published on the classification of VWD over the years. The earliest was an
article by Soulier and Larrieu in 1954 [5]; later articles include a study by Rodeghiero et al.
[6]. Landmark technologies in VWD classification and diagnosis include VWF antigen
(VWF:Ag) and ristocetin cofactor activity (VWF:RCo) in the 1970s, VWF multimer
analysis in the 1980s, and VWF DNA and RNA analysis in the 1990s/2000s. In the late
1970s, Arthur Bloom and I suggested seven diagnostic criteria for VWD:
1. A prolonged bleeding time.
2. Autosomal inheritance.
3. Reduced FVIII.
4. Reduced VWF:Ag.
5. A secondary rise in FVIII following transfusion.
6. Impaired ristocetin-induced platelet aggregation.
7. Reduced platelet adhesiveness.
In 1981 Ruggeri and Zimmerman published an article classifying variant VWD subtypes by
analysing functional characteristics and multimeric composition of VWF [7]. Later in 1987,
they extended their research and published an article specifying 11 subtypes of type 1 VWD
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and 13 for type 2 [8]. However, they also suggested a possible general classification as
follows:
1. Patients with quantitative abnormalities and no evidence of intrinsic functional
abnormality of VWF.
2. Patients whose VWF has low VWF:RCo.
3. Patients with enhanced responsiveness to ristocetin.
4. Patients with type 3 (severe) VWD.
Later, in 1994, the modern classification of the disease was published for the VWF
Scientific and Standardization Committee (SSC) Subcommittee of the ISTH [9]. It was
proposed that all VWD is caused by mutations at the VWF locus and divided quantitative
defects into partial deficiency (type 1) and severe deficiency (type 3). Qualitative defects
were divided into four subcategories: type 2A, 2B, 2M and 2N. In 2006, there was an update
on the classification [10] when it was stated that VWD is not restricted to VWF gene
mutations. Types 2A, 2B, 2M and 2N remain the same, and type 1 VWD includes partial
quantitative deficiency of VWF. Plasma VWF may contain mutant subunits, but has normal
functional activity relative to antigen level. The proportion of large multimers is not
decreased significantly. Treatment was proposed, based on the underlying type of VWD
summarized as in Table 1.
With regard to how to test for VWD, various tests have been devised including VWF:RCo,
platelet function analyser (PFA–100, Siemens Healthcare Diagnostics, Tarrytown, NY,
USA), ristocetin-induced platelet aggregation (RIPA) and VWF collagen binding assay
(VWF:CB). These could in the future be replaced or complemented by VWF gene analysis,
but there has been limited success to date. When differentiating between type 2 VWD
variants, a VWF:RCo/VWF:Ag ratio <0.6 is characteristic of types 2A and 2M, RIPA can be
used for type 2B, a low FVIII:C/VWF:Ag ratio for type 2N and loss of high-molecular
weight (HMW) multimers for types 2A and 2B. In type 3, there is virtually undetectable
VWF in the plasma. For type 1 VWD with a VWF:Ag level of <30 IU dL−1, phenotypic and
genetic assays can be used, as well as response to desmopressin (DDAVP) test. For type 1
VWD with a VWF:Ag level of >30 IU dL−1, phenotypic assays are of limited value, but
genetic assays can be used to study penetrance. For types 2 and 3 VWD, both phenotypic
and genetic assays can be used, and in the case of type 3 patients, genetic analysis can be
used for family studies and to aid in prenatal diagnosis.
What developments can we expect to happen over the next 50 years? These should include
full VWF locus sequencing and analysis including haplotypes, glycosylation patterns etc.; a
‘better’ VWF:RCo assay involving flow; a standardized VWF:CB, an understanding of the
role of non-VWF genes/loci in the regulation of VWF levels, designer treatments and gene
therapy.
Multimers (Ulrich Budde)
Circulating VWF is the product of synthesis, storage, secretion, circulation (shear stress),
interaction with its receptors and ADAMTS13 and other proteases. It is therefore important
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to analyse the structure of VWF from the patient’s plasma. Decreased synthesis of VWF
occurs in inherited type 1 VWD, and can also occur as acquired VWD as a result of
hypothyroidism, or ingestion of valproate. Increased clearance of VWF occurs in type 1,
2M, Vicenza and 2A VWD, and in the acquired syndrome in monoclonal gammopathy of
undetermined significance (MGUS) type IgG and myeloma, MGUS type IgM and in
Waldenströ m’s macroglobinaemia. Increased proteolysis occurs in type 2A VWD, and in
the acquired syndrome (AVWS) as a result of receptor increase, thrombocythaemia,
inherited cardiac defects, aortic stenosis, cardiac assist devices or as a result of treatment
with ciprofloxacin. Abnormal folding occurs in a subset of type 1 VWD (20–25% of type 1
patients) with a peculiar smeary pattern and in many cases an increased velocity of the
protein in the gel. Increased binding occurs in type 2B VWD (platelet type VWD) and there
have been sporadic case reports in acquired VWD. Dimerization and multimerization
defects occur in type 2A (IIC, IIC Miami and IID).
VWF: glycosylation and function (Mike Laffan)
Protein glycosylation has several important roles:
1. Structural (cell walls, extracellular matrix).
2. Protein properties (solubility, stability, susceptibility to proteolysis).
3. Trafficking (intra/extracellular).
4. Adhesion (cell–cell, cell matrix).
5. Mediating and modulating signalling (intra/extra-cellular).
With regard to VWF, ~ 20% is glycan by weight and ~ 13% of N-linked glycans carry ABO
blood sugars [11]. Occurrence of these asparagine-linked oligo-saccharides with blood
group A and B structures suggest that the repeated use of factor VWF/FVIII pooled
concentrate for the treatment of haemophiliacs could result in the production of antibodies
against VWF with a different blood group from that of the patient, and that this development
may be pathogenic. Out of the whole VWF protein comprised of 2050 amino acid residues,
12 N-linked and 10 O-linked glycan sites have been identified by cloning peptide
sequencing of mature VWF [12]. There is one unused site in C2 and four more potential
sites in propeptide from cDNA [12]. N-linked glycan sites are highly conserved. Caln-exin
and calreticulin are related proteins that comprise an endoplasmic reticulum (ER) chaperone
system that ensures the proper folding and quality control of newly synthesized
glycoproteins. There is clear evidence that ERp57, an enzyme that catalyses disulfide bond
formation, reduction and isomerization, participates in glycoprotein biogenesis either alone
or in tandem with calnexin and calreticulin (13; Fig. 3).
N-linked glycosylation is required for VWF expression. Out of 17 N-linked glycan sites,
four mutations affect secretion. These are N99Q (propeptide), N857Q (D′ domain), N2400Q
(C1 domain) and N2790Q (cys-teine knot). Creatine kinase glycosylation at N2790 is
required for dimerization. Functional effects of glycans include ADAMTS13 proteolysis. In
a study of the influence of ABO blood group on the rate of proteolysis of VWF by
ADAMTS13, it was found that the loss of collagen-binding activity was greater for VWF of
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group O compared with non-O VWF, in the rank order O ≥ B > A ≥ AB [14]. Specific N-
linked glycans involved in ADAMTS13 cleavage are N1515 and N1574, which both occur
in the A2 domain of VWF. Of the two, VWF–N1574Q is more susceptible to ADAMTS13
cleavage. VWF multimeric composition is regulated in plasma by ADAMTS13. A study by
McGrath et al. [15] in 2010 showed that removal of sialic acid impairs ADAMTS13
cleavage and abolishes the ABO effect. Progressive shortening of N-linked glycan sugars
(A–H–Bombay-Swainsonine–PNGase) results in more rapid cleavage of VWF. Conversely,
removal of sialic acid makes VWF more resistant to ADAMTS13 cleavage. A loss of sugars
is associated with increased affinity for ADAMTS13. There is a major effect from a single
glycan at N1574.
With regard to VWF clearance, the ABO effect is probably mediated by an effect on
clearance. A study by Sweeney et al. in 1990 showed that in the RIIIS/J mouse, glycans
were able to modulate VWF clearance [16].
O-linked glycans attach to serine or threonine residues after protein folding. Long O-linked
glycans are found in mucins. Short O-linked glycans occur at the hinge regions. O-linked
glycans provide stiffness and protect against proteolysis. Thus, glycans regulate processing,
ADAMTS13 cleavage, clearance and possibly other functional interactions.
Classification of VWD (Bob Montgomery)
According to the mechanistic classification of VWD, decreased synthesis of VWF is found
in types 1 and 3 VWD, abnormal interaction with platelets occurs in type 2B (increased
interaction) and type 2M (decreased in some cases; there are multiple causes of this variant),
abnormal interaction with collagen is found in type 2M, also types 2A and 2B, abnormal
clearance occurs in type 1C, also types 2A and 2B, and abnormal interaction with FVIII
occurs in type 2N (which may be misdiagnosed as haemophilia). In type 1C VWD the half-
life of VWF is reduced, but unlike type 1 VWD, FVIII and VWF are both reduced. Blood
group is also an important consideration, as VWF is 25% lower in people with blood group
O, and FVIII is similarly reduced in plasma secondary to this clearance. A common
polymorphism present in >60% of African Americans renders the VWF:RCo assay
unreliable for assessing VWF function (Fig. 4; 17). Assays developed by the Hamburg
Group and the Milwaukee Group to circumvent this problem have been developed.
Collagen-binding defects as a cause of type 2M VWD are underdiagnosed because
VWF:CB assays are not commonly included in VWD screening.
Pharmacokinetics and laboratory assays when treating VWD (Jerzy
Windyga)
The aim of therapy in VWD is to control or prevent bleeding through the specific correction
of the dual defect of haemostasis, i.e. abnormal platelet adhesion-aggregation due to defect
or deficiency of VWF and abnormal intrinsic coagulation due to low FVIII levels. Therapy
aims to increase plasma levels of VWF. Treatment strategies are as follows: non-
replacement therapy to increase VWF and FVIII with DDAVP, replacement therapy
(pdVWF/FVIII concentrates, pdVWF concentrates), adjuvant treatments to promote haemo-
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stasis and wound healing (fibrinolysis inhibitors, platelet concentrates, oestrogen-
progesterone preparations and topical agents) and combination therapy. If DDAVP is to be
used, a DDAVP test should be performed to establish the patient’s individual response. The
dose is 0.3 μg kg−1. Response to DDAVP should be assessed at 1 h after infusion. FVIII:C
and VWF:RCo plasma levels should be assessed at 4 h post infusion to determine the pattern
of clearance. Factors to consider when deciding on treatment are as follows:
1. The FVIII and VWF levels and VWD subtype.
2. The FVIII and VWF response to DDAVP if previously given.
3. The patient’s previous bleeding history and response to treatment.
4. The nature of the bleeding episode.
5. Presence of an inhibitor to VWF.
6. Potential risks of treatment (e.g. factor VIII accumulation after multiple injections
[18]).
Patients who need to be monitored are those treated repeatedly with DDAVP, those with
accelerated plasma clearance of VWF/FVIII and those in whom treatment is required for
more than 3 days. Other indications for monitoring of therapy include major surgery, life-
threatening bleeds, minor surgeries in severe VWD, and if there is a risk of delayed
haemorrhage. For those patients in whom DDAVP is ineffective or prolonged treatments are
required, or if DDAVP is contraindicated, treatment with VWF/FVIII or VWF concentrates
is indicated. Treatments are Haemate-P, Wilate, Alphanate, Fandhi and Wilfactin. For
treatment of spontaneous bleeding episodes, daily doses of 20–60 IU kg−1 of VWF/FVIII
are required to maintain FVIII:C levels >30 U dL−1 until bleeding stops (usually 2–4 days).
For prophylaxis for delivery and the puerperium, daily doses of 50 IU kg−1 are required to
maintain FVIII:C level >50 U dL−1 for 3–4 days. For prophylaxis for dental extractions or
invasive procedures, a single dose of 30 IU kg−1 of VWF/FVIII is required to maintain the
FVIII:C level at > 50 U dL−1 for 12 h [19].
Genetics of VWD (Anne Goodeve)
This presentation examined where genetic testing in VWD can help clarify disease type and
suggested appropriate management. In type 3 VWD, large deletions and other null mutations
(nonsense, splice, small deletions and insertions) result in lack of VWF protein and there are
also a small proportion of missense mutations. VWF dosage analysis using multiplex
ligation-dependent probe amplification (MLPA) can be used to detect homozygous and
heterozygous deletions and duplications of ≥1 exon. Sequencing of exons 2–52 is performed
to identify point mutations. In type 3 VWD, the phenotype is usually clear. The cut-off
between severe type 1 and type 3 may be equivocal, in which case mutation analysis may
help to clarify the disease type.
In type 1 VWD, analysis of the entire VWF gene is required for complete point mutation
analysis as mutations are found throughout the gene. Mutations are detected in up to 70% of
patients.
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Type 2 VWD largely results from missense mutations in specific VWF domains that affect a
specific protein function. In type 2B VWD, enhanced ristocetin-induced platelet aggregation
(RIPA) may be the only identifying feature. There is a loss of HMW multimers due to
clearance of VWF from plasma along with platelets and enhanced ADAMTS13 sensitivity.
Type 2B mutations are missense mutations in a discrete region of the A1 domain encoded by
exon 28 (Fig. 5 [20]).
In type 2M VWD, mutations affect the ability of VWF to bind platelet GpIbα or to
subendothelium. They are largely located in the A1 and A3 domains. There is no loss of
HMW multimers.
Patients with type 2A VWD have a loss of HMW multimers that can result from different
mutation types and locations that correlate with subtle differences in multimer profile.
Dimerization, multimerization, extent of intracellular retention, clearance from the
circulation and sensitivity to ADAMTS13 cleavage can all be affected. Most type 2A VWD
is dominantly inherited.
In type 2N VWD, missense mutations are detected in the D′ and D3 domains. The R854Q
mutation is particularly common in European populations. Mutations are recessively
inherited. Genetic analysis is important to clarify or exclude VWD diagnosis and can
indicate phenotype-genotype correlations, which can be helpful in establishing the response
to DDAVP.
Treating the paediatric patient (Pia Petrini)
Should children with VWD be assessed differently to adults? According to the ISTH [10],
the criteria for diagnosis are a significant bleeding history, a family history or relevant VWD
mutation and laboratory determination, but only 4.5% of children fulfil these criteria [21].
This study concluded that ISTH criteria failed to identify the majority of children and
adolescents who presented with significant mucocutaneous bleeding. The diagnosis is
difficult in children, who are not yet challenged with operations, tooth extractions or
menorrhagia, and 25% of the normal population may have bleeding symptoms such as
epistaxis and bruising. Accordingly taking a mucocutaneous bleeding history is extremely
important. With regard to neonates with a family history, they should be tested if type 3
VWD is a possibility or the child has bleeds, but not if the child is doing well after a normal
delivery. VWF and FVIII can be raised in newborns, which complicates the diagnosis as
type 1 subtypes may be missed. Treatment involves cyclokapron or DDAVP. Intranasal
application of DDAVP is of special interest for children as it does not involve the use of
needles. However, it is not used before school age in our centre because of the risk of
hyponatraemia. Long-term prophylaxis, which has become a state-of-the-art approach in
haemophilia, is not very common in VWD. However, more recent data suggest that many
VWD patients could benefit from prophylactic treatment with VWF-containing
concentrates. In a study of 35 Swedish VWD patients who required prophylaxis (mainly
because of nose/mouth bleeds and joint bleeds, Fig. 6), there was a substantial overall
reduction in bleeding episodes and there were no signs of arthropathy in children who began
prophylaxis before the age of 5 years [22].
BERNTORP et al. Page 7
Haemophilia. Author manuscript; available in PMC 2014 September 22.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
In a study of bleeding risk in 41 children with type 1 VWD undergoing adenotonsillar
surgery [23], the children were treated according to the Children’s Hospital of Philadelphia
protocol involving intravenous DDAVP, oral aminocaproic acid and overnight observation.
Seven patients developed delayed (>24 h) postoperative haemorrhage requiring intervention,
of whom five were treated with cautery and the remaining two responded to DDAVP and
aminocaproic acid. The authors concluded that despite treatment to decrease the risk of
postoperative haemorrhage, the incidence of haemorrhage was higher in pretreated patients
with type 1 VWD than in children without bleeding disorders.
It is also important to consider the diagnosis of VWD in children presenting with head
injury. In a study of an 11-month girl who presented to hospital with a massive subdural
haematoma and bilateral haemorrhages following an allegedly minor fall, the parents were
initially accused of child abuse [24]. Retinal haemorrhages and subdural haematoma are
typical signs in the shaken baby syndrome. In this case, there was no bruising and no prior
bleeding tendency was reported. Although initial analyses were normal, repeated testing led
to a diagnosis of mild type 1 VWD. Police charges against the parents were then dropped.
The case highlights the importance of considering VWD as a possible cause of head injury
in young children.
Prophylaxis in VWD (Erik Berntorp)
Prophylaxis is well established in haemophilia A, but not in VWD. The Swedish experience
of VWD prophylaxis is the largest cohort followed for the longest period of time. A total of
37 patients have been studied: three with type 1 VWD, three with type 2A, three with type
2B and 28 with type 3 [22,25]. Age at the start of prophylaxis was a median of 13 years (1–
61 years). Indications for prophylaxis were mostly nose, mouth and joint bleeds, which were
graded as serious to life-threatening. Treatment was with Haemate/Humate-P one to three
times a week. Prophylaxis resulted in a substantial reduction of bleeding episodes. Patients
who began prophylaxis prior to 5 years of age have had no joint bleeds and no clinical signs
of arthropathy. The results show that long-term prophylaxis is warranted in most patients
with type 3 VWD and in other subtypes with severe bleeding tendencies. Other small
cohorts have been published with favourable results [26–29]. An international effort has
been initiated [the von Willebrand’s Disease Prophylaxis Network (VWD PN)] and is
ongoing as several issues remain such as dosing, indication and choice of concentrates. The
aim of the Network is to investigate the role of prophylaxis in clinically severe VWD that is
non-responsive to other treat-ment(s), involving a consensus of 30 centres in Europe and 44
in North America. From the collection of data from a large number of centres it will be
possible to establish the number of people with VWD under care, the distribution of types of
VWD and the frequency and indications for use of prophylaxis. Results to date show that
there are a greater number of patients with type 3 VWD in Europe, 7% compared with 4% in
North America. Use of prophylaxis in type 3 VWD varied significantly (P = 0.0004) by
region: 28.7% in Europe vs. 12.2% in North America. Use of prophylaxis in types 1 and 2
VWD was rare in both regions. Indication for prophylaxis was mainly joint bleeds (40%),
followed by epistaxis/oral (23%) and did not differ greatly by geographic region. When
comparing prophylaxis in VWD to that in haemophilia, the dosing interval can be longer in
VWD than in haemophilia.
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The VWD International Prophylaxis (VIP) Study is a combination of prospective and
retrospective studies. The primary aims are to identify subjects with VWD who may benefit
from prophylaxis by determining patterns of bleeding prior to enrolment; study the effect of
prophylaxis on bleeding frequency; and establish optimal treatment regimens for joint
bleeding, gastrointestinal (GI) bleeding, epistaxis and menorrhagia. Secondary objectives
include the determination of how quality of life at baseline is related to bleeding history and
whether or not changes in bleeding frequency are associated with changes in quality of life.
The prospective study is a non-randomized, dose-escalation study enrolling 40–50 patients
for each bleeding indication: joint, epistaxis, gastrointestinal and menorrhagia. Follow-up is
for 1 year, with visits every 3 months. Use of VWF/FVIII products licensed for the
treatment of VWD is permitted. The retrospective study includes patients who have been on
prophylaxis for at least 6 months, with data collected from study centres and diaries; the aim
is to compare bleeding frequency pre and post prophylaxis. A third area is a retrospective
study of the natural history of GI bleeding, looking at patients with a history of GI bleeding
due to angiodysplasia or unexplained by other factors. As at 14 July 2010, a total of 69
centres with 83 patients were participating in the VIP study. The primary area for
prophylaxis was epistaxis in the prospective study (66.7%) and joint bleeding in the
retrospective study (25.7%; Table 2; [30]). It was concluded that the early data provide
strong support for the use of prophylaxis for people most severely affected by VWD. They
also support prospective efforts to identify optimal prophylactic treatment regimens for
those at greatest risk for bleeding.
Managing surgeries and interventions (Mario von Depka)
In prospective clinical trials, 32 VWD patients undergoing 57 surgical procedures were
treated with a VWF/FVIII concentrate (Wilate® Octapharma GmbH, Langenfeld, Germany).
More than 68% of the procedures were performed in patients with severe VWD type 3. Ten
of the 57 procedures were in paediatric patients. Thirty procedures were minor and the
remaining 27 were major surgery. The mean dose per infusion was 34 IU kg−1 in total (36
IU kg−1 in minor, 31 IU kg−1 in major surgeries) and 31.9 IU kg−1 in paediatric patients.
Dosing and monitoring was performed according to FVIII:C or VWF:RCo or both
parameters. Wilate’s overall haemostatic efficacy was rated as excellent/good in 96% (51/53
of rated cases). There was no development of inhibitors to VWF or FVIII or any thrombotic
events. After multiple dosing, no accumulation of FVIII was observed. It was concluded that
Wilate provides effective cover in patients with VWD undergoing surgical procedures.
When VWD comes into age – VWD in geriatrics (Wolfgang Miesbach)
Between 1962 and 2002, average life expectancy in Western Germany increased from 67.1
to 75.6 years in men and from 72.7 to 81.3 years in women. The largest contribution to the
increase in life expectancy came from the age group 65 years and older [31]. In the Swedish
population, there were 948 patients with haemophilia for the period 1831–1980. For them
life expectancy has increased fivefold from 11 years (1831–1920) to 56.8 years (1961–1980;
32]. Patients with VWD are also living longer, and the elderly VWD patient is also likely to
have other co-morbidities such as hypertension, diabetes mellitus, osteoporosis,
atherosclerotic and thromboembolic diseases and malignancies (Fig. 7). In the elderly, more
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patients have the severe form of VWD and more patients have acquired VWD as a result of
medication, malignancies (clonal monoclonal gammopathy, or lymphoproliferative or
myeloproliferative disorders; [33]) or operations. In younger patients the primary bleeding
symptoms are oral cavity bleeding, epistaxis, cutaneous bleeding, menorrhagia, bleeding
from minor wounds, tooth extraction and postpartum haemorrhage, whereas in the elderly
the primary symptoms are GI bleeding, bleeding following surgery/tooth extraction and
haemarthrosis [34,35]. Treatment with DDAVP is contraindicated in the elderly as it can
cause vasoconstriction and hyponatraemia. An online survey is proposed to investigate
elderly patients with VWD. This will improve our knowledge of the disease in the elderly.
Gene therapy for VWD: one step at a time (David Lillicrap)
Type 3 VWD causes serious problems such as haemarthroses and GI tract bleeding. Since
1975, different virus vectors have been developed in order to carry functional genes for gene
transfer. However, no successful clinical trials have been reported to date. Recently, a new
method for altering a single basepair of target DNA was reported using chimeric RNA/DNA
oligonucleotides. In patients with haemophilia A or B, the mutations (coagulation factors
VIII and IX) are well characterized and the mutation-repair method using chimeric
RNA/DNA oligo-nucleotides could provide an alternative for the treatment of haemophilia
[36]. In VWD there are challenges to gene transfer, with VWF cDNA being irreducible at
8.4 kb. The advantages of a mouse model are genetic homogeneity, consistent VWF cDNA
(no influence of polymorphisms), good study population numbers and good in vivo
thrombosis models. The challenges of using the VWF KO mice are species-specific VWF
processing and ligand interaction. Three common recurrent type 2B VWD mutations
introduced into mouse VWF cDNA are V1316M, R1306W and R1341Q. Wild type residues
are conserved between human and mouse. Early evidence suggests that reconstitution of the
plasma compartment alone, with VWF expressed from the liver, recapitulates the
phenotypes of both qualitative and quantitative forms of VWD.
Role of FVIII in VWF replacement (Erik Berntorp)
FVIII is needed in addition to VWF because of low levels in type 3 VWD and other
subtypes. In patients with type 3 VWD (and those with type 2N VWD), the lack of FVIII–
VWF binding results in a secondary defi-ciency of FVIII and the FVIII level is usually
<10% of normal in patients with type 3 VWD [27,37]. Joint bleeds are common, especially
in type 3 VWD. A common concern is that FVIII will accumulate if combined VWF/FVIII
concentrates are given. Another concern is that there is an increased risk of venous
thromboembolism (VTE) with combined concentrates. The overall incidence of VTE in
VWD has been reported to be seven cases in 12 640 yearly treatments over 10 years [38],
i.e. one case per 1806 treatment years. Only a few VTE events have been reported for
Humate-P. In all cases, there was a connection with risk factors and levels of FVIII:C/
VWF:RCo were above 100–200%. The efficacy record is outstanding for VWF/FVIII
concentrates.
With regard to purified concentrates, the risk is that FVIII levels can be too low. In 1992,
Lethagen showed that there was a lag time before achieving a good plasma FVIII level with
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Wilfactin, a pure VWF concentrate almost devoid of FVIII [39]. Use of purified VWF
concentrates requires co-administration of FVIII, or an extra dose of concentrate. The
addition of FVIII is probably superfluous in concentrates if used for continuous prophylaxis
or used for scheduled surgery – but more studies are needed.
Inhibitors in VWD (Augusto B. Federici)
Compared to patients with moderate to severe haemophilia A, who may develop anti-factor
VIII inhibitors in ~ 20–30% of cases, the antibodies against VWF (anti-VWF inhibitors) are
a rare complication of replacement therapy in transfused patients with inherited type 3
VWD. These anti-VWF inhibitors are allo-antibodies and for many years have been
associated only with deletions of the VWF gene causing VWD type 3: they have never been
identified in patients with types 1 or 2 VWD.
The occurrence of an alloantibody against VWF in multitransfused patients with VWD type
3 was first reported in 1974 [40]. In the most recent retrospective study of the Italian
Association of Hemophilia Centers (AICE), 96 VWD type 3 patients (5.8%) were identi-fied
among the 1650 cases included in the registry [41] with a prevalence of 1.6 per million of
population; in this registry anti-VWF inhibitors were identified in seven patients only, from
three VWD type 3 families. In such cases, VWF concentrates are not only ineffective, but
may even cause post infusion life-threatening anaphylaxis [42], due to the formation of
immune complexes. Inhibitors can also interact with FVIII; if they occur, combined VWF/
FVIII products should not be used, but pure VWF or rF7a should be used instead.
Unfortunately, no general consensus has been reached for testing these anti-VWF antibodies
in VWD type 3. Assays are currently available in only a few specialized laboratories and
they mimic the Bethesda assays for haemophilia inhibitors by performing VWF and FVIII
activities in patient-normal pool plasma mixtures after 2 h’ incubation at 37°C. The titre of
anti-VWF inhibitor is calculated by the current dilution of VWD plasma inhibiting 50% of
normal plasma pool diluted 1:2 compared to control mixture. Due to the different functions
of VWF, all its activities should always be measured, such as anti-VWF:antigen, anti-
VWF:RCo, anti-VWF:CB and anti-FVIII. Negative results by mixing tests cannot exclude
inhibitors completely, since they might affect non-functional regions of the VWF protein.
Some authors have recently proposed an indirect assay to test these anti-VWF antibodies
using a sandwich enzyme-linked immunosorbent assay (ELISA). The sensitivity of this
assay is very promising, but its specificity is low (many false-positive results). All these
techniques should be standardized prospectively by a multicentre study organized by the
Members of the European Group on VWD3 on behalf of the ISTH-SSC Subcommittee on
VWF.
Current treatment guidelines – experiences from the UK (Mike Laffan)
In the UK, there are 101 centres. Current treatment guidelines (2004) are being followed, but
there are some concerns about practice. Guidelines on diagnosis were published in 2004
[43]. They were written by a working party, circulated to the UK Haemophilia Centre
Doctors’ Organization (UKHCDO) and peer reviewed. Requirements for diagnosis of VWD
are as follows:
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1. A personal history of (mucosal) bleeding.
2. Decreased functional VWF levels.
3. A mutation in the VWF gene or family history of bleeding that segregates with (2).
There are problems with all of these criteria. A significant bleeding history includes
epistaxis for more than 20 min, prolonged bleeding (>15 min) from trivial wounds and
prolonged or excessive postoperative bleeding [44]. For family history, there should be a
first-degree relative affected, or two-second-degree relatives affected. Preliminary tests
include full blood count, coagulation screen, PFA–100, FVIII, VWF:Ag, VWF:RCo,
VWF:CB and RIPA. Further tests may include FVIII binding assay and genetic analysis.
The bleeding time does not have a role as a screening test for VWD, although it is of value
in the composite assessment of haemostasis. The VWF:Ag should be measured using an
assay whose limit of detection is <1 IU dL−1. A platelet-based assay for VWF:RCo should
be used to assess VWF:RCo (not an ELISA assay). Both VWF:RCo and VWF:CB should be
obtained to improve the ability to detect type 2 variants and to more clearly define type 1
VWD. The VWF multimer analysis has a role in sub-classification of VWD; it is
inappropriate to perform this test until a diagnosis of VWD has been confirmed. To
minimize the risk of misdiagnosis, VWF:Ag and function must be measured in samples
obtained on at least two occasions, with consistent results. It is important to avoid
circumstances that may be confounding (stress, pregnancy, etc.). The ISTH 1994 criteria are
used to classify the type of VWD [9]. Rather than ask does this patient have VWD, it is
important to assess whether they are at risk of bleeding, either spontaneously or following
injury or invasive procedures, and then decide what treatment, if any, is required, and
whether other family members are also at risk. Guidelines on management of VWD were
published in 2004 by the UKHCDO [18]. Management of the patient with VWD depends on
the following:
1. The nature of the bleeding episode.
2. The FVIII and VWF levels and the VWD type.
3. The patient’s previous bleeding history and response to treatment.
4. The FVIII and VWF response to DDAVP if given previously.
5. Presence of an inhibitor.
6. Potential risks of treatment.
Treatment options include tranexamic acid (useful alone or as an adjunct including as a
mouth wash), DDAVP (preferred to blood products when effective), concentrates (need to
avoid excessive rise in FVIII) and treatments for menorrhagia (e.g. tranexamic acid and
Mirena IUCD). For pregnant patients, vaginal delivery is acceptable if VWF:RCo is >40 IU
dL−1, and a Caesarean section is acceptable if VWF:RCo >50 IU dL−1. In type 1 VWD
patients, it is important to watch out for rebleeding at 4–5 days post delivery. For patients
with types 2 and 3 VWD, the patient should be advised against having an epidural. If the
foetus is at risk of having types 2 or 3 VWD, foetal scalp monitoring, forceps and ventouse
delivery should be avoided. Regardless of the mode of delivery, newborns at risk of types 2
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and 3 VWD need to be tested for VWD using cord blood and assessed to exclude
intracranial haemorrhage.
Current treatment guidelines – experiences from Scandinavia (Riitta
Lassila)
In 1926, Erik von Willebrand published the first report of a patient with VWD [1]. Since
then there have been key observations and commitment to research in VWD in Nordic
countries. The Nordic hemophilia council (NHC) is a society of physicians and related
experts from Nordic haemophilia centres in Denmark, Finland, Iceland, Norway and
Sweden. The NHC holds a general annual meeting and forms a base for co-operation
between the Nordic centres. The NHC is responsible for the management of the society and
implementation of the Nordic guidelines for bleeding disorders. Joint projects include the
evaluation of the prevalence of bleeding disorders, and the evaluation of the products used
and their pricing in Nordic countries. A flow chart for the diagnosis of VWD is shown in
Fig. 8 [45–47].
Differential diagnosis of type 1 VWD includes platelet disorders and effect of concurrent
medications such as selective serotonin reuptake inhibitors (SSRIs) and omega 3. Regular
prophylaxis with a VWF concentrate should be considered in some patients with types 2 and
3 VWD. Prophylactic treatment should also be considered if nose bleeds, menorrhagia or
gastrointestinal bleeds cause significant anaemia despite iron supplementation, have an
impact on social life and/or all other treatment modalities have failed. As prophylaxis, a
VWF concentrate in a dose of about 50 IU VWF:RCo kg−1 i.v. administered 2–3 times per
week is used to prevent bleeds. Levels of VWF:RCo and FVIII:C should be monitored when
repeated doses of the concentrate are given.
Current treatment guidelines – experience from the USA (Gil White)
In 2008, the National Heart, Lung and Blood Institute (NHLBI) in the USA published
evidence-based guidelines on the diagnosis and management of VWD [48].
It was proposed that patients should be asked a series of questions:
1. Have you or a blood relative ever needed medical attention for a bleeding problem,
or have you been told you had a bleeding disorder? During or after surgery? With
dental work? With trauma?
2. Do you have or have you ever had liver or kidney disease? A blood or bone
marrow disorder? High- or low platelet count?
3. Are you presently taking or have you taken anticoagulation? NSAIDs?
4. Do you have a blood relative with a bleeding disorder like VWD or haemophilia
A?
5. Have you ever had prolonged bleeding from trivial wounds, lasting >15 min or
recurring spontaneously within 7 days?
6. Have you ever had excessive bleeding after surgical procedures?
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7. Have you ever had bruising, with minimal or no trauma?
8. Have you ever had a spontaneous nosebleed that lasted >10 min?
9. Have you ever had excessive bleeding after dental extractions?
10. Have you ever had unexplained blood in your stool?
11. Have you ever had anaemia that required a blood transfusion?
12. Have you ever had heavy menses, with clots >1 inch in diameter.
During the consultation, evidence for a bleeding disorder should be sought. Evidence of
other causes of increased bleeding should also be looked for, such as jaundice, splenomegaly
and arthropathy. If the diagnosis of VWD seems possible, the initial evaluation should
include VWF:RCo, VWF:Ag and FVIII, as well as complete blood count, platelet count,
prothrombin time, partial thromboplastin time and thrombin time. If after these tests the
diagnosis of VWD is supported, other tests should be carried out including VWF:RCo/
VWF:Ag ratio, VWF multimer analysis and VWF:CB. It is important to eliminate stress as
much as possible when taking blood samples, as this may falsely elevate VWF and FVIII
levels. The presence of an inflammatory illness may also elevate VWF and FVIII levels, as
may pregnancy or administration of oral contraceptives.
Once the diagnosis is confirmed, treatment of patients with VWD is aimed at cessation of
bleeding and prophylaxis for surgical procedures. Epistaxis and oropharyngeal, soft tissue,
or minor bleeding should be treated with intravenous or intranasal DDAVP, if appropriate,
based on trial testing. For prophylaxis for minor surgery, initial treatment should be
expected to achieve VWF:RCo and FVIII activity levels of at least 30 IU dL−1 and
preferably higher than 50 IU dL−1. For persons with mild to moderate VWD,
antifibrinolytics combined with DDAVP are generally effective for oral surgery. VWF
concentrates should be administered to those in whom DDAVP is contraindicated or who
bleed on DDAVP. Whenever possible, all major surgical procedures and bleeding events
should be treated in hospitals with 24-h laboratory capability and monitored by a team that
includes a haematologist and surgeon skilled in the management of bleeding disorders. For
severe bleeding or for prophylaxis during major surgery, initial target VWF:RCo and FVIII
should be at least 100 IU dL−1. Subsequent dosing should maintain VWF:RCo and FVIII
above a trough of 50 IU dL−1 for at least 7–10 days. In an adolescent or adult woman who
does not desire pregnancy but may in the future, the first choice of therapy for menorrhagia
should be combined oral contraceptives. For a woman who desires pregnancy, DDAVP,
antifibrinolytics, or a VWF concentrate may be tried to control menorrhagia. For pregnant
patients, those with type 1, type 2, or type 3 VWD, with FVIII or VWF:RCo levels < 50 IU
dL−1 or a history of severe bleeding:
1. Should be referred to a centre that has high-risk obstetrics capabilities and expertise
in haemostasis for prenatal care, delivery, termination of pregnancy, or miscarriage.
2. Should receive prophylaxis with DDAVP or VWF concentrate before invasive
procedures.
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3. Should achieve VWF:RCo and FVIII levels of at least 50 IU dL−1 before delivery
and maintain those levels for 3–5 days.
Patients with AVWS and who require surgery should be considered for a trial of therapy
with DDAVP and/or VWF concentrate, with monitoring of VWF:RCo and FVIII, to
evaluate for accelerated clearance of VWF. For patients with AVWS and who bleed
excessively despite DDAVP and VWF concentrate, treatment with high-dose IVIG should
be considered.
Concluding remarks (Erik Berntorp)
The 2010 Åland meeting was as memorable as a previous meeting held in 1998 [49]. The
historical atmosphere, the friendly and knowledgeable participants and the venue located
among 5 000 beautiful and unspoiled islands will help us all to improve the situation for
patients with VWD. Hopefully this was not the last Åland conference on VWD.
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Fig. 1.
The Åland islands.
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Fig. 2.
Hjördis’ grave.
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Fig. 3.
N-linked glycosylation and endoplasmic reticulum quality control. Adapted with permission
from The Company of Biologists Ltd [13].
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Fig. 4.
VWF:RCo assay compared with GPIb complex-binding assay. The first two columns show
VWF:RCo/VWF:Ag ratio (●) for subjects with and without the D1472H polymorphism.
The second two columns show the GPIb complex-binding assay/VWF:Ag ratio (○) for
subjects with and without the D1472H polymorphism. The mean value for each group is
listed at the top of the graph. Error bars represent ± 1SD. Reproduced from [17] with
permission from the American Society of Hematology (ASH).
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Fig. 5.
Type 2B VWD mutations. Missense mutations in discrete region of A1 domain, exon 28.
Adapted from [20] with permission from Elsevier.
BERNTORP et al. Page 22
Haemophilia. Author manuscript; available in PMC 2014 September 22.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 6.
Clinical indication for prophylaxis by age at commencement of therapy (reproduced from
ref. 22 with permission from Blackwell Publishing Ltd).
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Fig. 7.
Co-morbidities in the elderly VWD patient.
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Fig. 8.
Flow chart of the diagnosis of von Willebrand’s disease. Adapted from [45] with permission
from the Ferrata Storti Foundation.
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Table 1
Recommended treatment of VWD.
Type of VWD Treatment Alternative
1 DDAVP VWF/FVIII concentrate
2A VWF/FVIII concentrate DDAVP
2B VWF/FVIII concentrate None
2M VWF/FVIII concentrate DDAVP
2N VWF/FVIII concentrate DDAVP
3 VWF/FVIII concentrate Platelet concentrate
VWD, von Willebrand’s disease; DDAVP, desmopressin; FVIII, factor VIII.
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Table 2
Primary indication for prophylaxis*.
Prospective Retrospective Total
Site N (%) N (%) N (%)
Epistaxis 4 (66.7) 8 (22.9) 12 (29.3)
GI bleeding 1 (16.7) 7 (20.0) 8 (19.5)
Joint bleeding 1 (16.7) 9 (25.7) 10 (24.4)
Menorrhagia 0 (0.0) 4 (11.4) 4 (9.8)
Other 0 (0.0) 4 (11.4) 4 (9.8)
Mixed 0 (0.0) 3 (8.6) 3 (7.3)
Total 6 (100.0) 35 (100.0) 41 (100.0)
*
Defined as the most severe symptom, or the source of the most significant morbidity.
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